BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15155114)

  • 1. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
    Dobnig H
    Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
    Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
    Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
    N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of teriparatide in sequential and combination therapy of osteoporosis.
    Meier C; Lamy O; Krieg MA; Mellinghoff HU; Felder M; Ferrari S; Rizzoli R
    Swiss Med Wkly; 2014; 144():w13952. PubMed ID: 24896070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
    Kaufman JM; Orwoll E; Goemaere S; San Martin J; Hossain A; Dalsky GP; Lindsay R; Mitlak BH
    Osteoporos Int; 2005 May; 16(5):510-6. PubMed ID: 15322742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.
    Zanchetta JR; Bogado CE; Ferretti JL; Wang O; Wilson MG; Sato M; Gaich GA; Dalsky GP; Myers SL
    J Bone Miner Res; 2003 Mar; 18(3):539-43. PubMed ID: 12619939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriparatide: a review.
    Quattrocchi E; Kourlas H
    Clin Ther; 2004 Jun; 26(6):841-54. PubMed ID: 15262455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
    Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
    Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
    Geusens P; Marin F; Kendler DL; Russo LA; Zerbini CA; Minisola S; Body JJ; Lespessailles E; Greenspan SL; Bagur A; Stepan JJ; Lakatos P; Casado E; Moericke R; López-Romero P; Fahrleitner-Pammer A
    J Bone Miner Res; 2018 May; 33(5):783-794. PubMed ID: 29329484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
    Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
    Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
    Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
    J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of parathyroid hormone.
    Cosman F; Lindsay R
    Curr Osteoporos Rep; 2004 Mar; 2(1):5-11. PubMed ID: 16036076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.